Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2005;330:1269 (28 May), doi:10.1136/bmj.330.7502.1269
| The first 150 words of the full text of this article appear below. |
EditorVerma and Strauss say that, compared with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers do not reduce (and may increase) the risk of myocardial infarction.1 Their claim represents an incomplete, inaccurate, and misleading "analysis" of the evidence.
They did not cite the two largest studies that randomised patients to an ACE inhibitor or angiotensin receptor blockers and had the statistical power to evaluate cardiovascular outcomes.2 3 These had twice as many myocardial infarctions as their trials combined (table). As none of their trials randomised these two treatments, their conclusions depend on indirect comparisons, small numbers of events and are unreliable. OPTIMAAL (379 patients with MI in the captopril group and 384 losartan) and VALIANT (798 total myocardial infarctions in captopril group, 796 valsartan) strongly refute the authors' hypothesis.
Other data were selectively and incorrectly citedfor example, mentioning the only CHARM trial with an excess of myocardial infarctions in the candesartan
John McMurray, professor of medical cardiology1
1 Department of Cardiology, Western Infirmary, Glasgow G11 6NT j.mcmurray@bio.gla.ac.uk